A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Emily G GreengardRobin WilliamsBranden MoriarityXiaowei LiuCharles G MinardJoel M ReidTerrence FisherElizabeth EvansDesa Rae PastoreMaurice ZaudererStephan D VossElizabeth FoxBrenda J WeigelPublished in: Pediatric blood & cancer (2024)
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.